An Overview of ADAM9: Structure, Activation, and Regulation in Human Diseases

被引：74

作者：

Chou, Cheng-Wei ^{[1
,2
]}

Huang, Yu-Kai ^{[1
]}

Kuo, Ting-Ting ^{[3
]}

Liu, Jing-Pei ^{[1
]}

Sher, Yuh-Pyng ^{[1
,3
,4
]}

机构：

[1] China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan

[2] Taichung Vet Gen Hosp, Div Hematol Med Oncol, Dept Med, Taichung 407, Taiwan

[3] China Med Univ Hosp, Ctr Mol Med, Taichung 404, Taiwan

[4] China Med Univ, Chinese Med Res Ctr, Taichung 404, Taiwan

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 20期

关键词：

ADAM9; biological function; inflammation; cancer; HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; LUNG-CANCER; CELL-PROLIFERATION; TARGETING ADAM9; METALLOPROTEASE-DISINTEGRIN; CRYSTAL-STRUCTURES; ENDOTHELIAL-CELL; TUMOR-CELLS; EXPRESSION;

D O I：

10.3390/ijms21207790

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

ADAM9 (A disintegrin and a metalloprotease 9) is a membrane-anchored protein that participates in a variety of physiological functions, primarily through the disintegrin domain for adhesion and the metalloprotease domain for ectodomain shedding of a wide variety of cell surface proteins. ADAM9 influences the developmental process, inflammation, and degenerative diseases. Recently, increasing evidence has shown that ADAM9 plays an important role in tumor biology. Overexpression of ADAM9 has been found in several cancer types and is correlated with tumor aggressiveness and poor prognosis. In addition, through either proteolytic or non-proteolytic pathways, ADAM9 promotes tumor progression, therapeutic resistance, and metastasis of cancers. Therefore, comprehensively understanding the mechanism of ADAM9 is crucial for the development of therapeutic anti-cancer strategies. In this review, we summarize the current understanding of ADAM9 in biological function, pathophysiological diseases, and various cancers. Recent advances in therapeutic strategies using ADAM9-related pathways are presented as well.

引用

页码：1 / 22

页数：22

共 127 条

[41]

Hu DD, 2017, AM J CANCER RES, V7, P2070

[42] MicroRNA-126 inhibits proliferation and metastasis in prostate cancer via regulation of ADAM9 [J].

Hua, Yibo ;

Liang, Chao ;

Miao, Chenkui ;

Wang, Shangqian ;

Su, Shifeng ;

Shao, Pengfei ;

Liu, Bianjiang ;

Bao, Meiling ;

Zhu, Jundong ;

Xu, Aiming ;

Zhang, Jianzhong ;

Li, Jie ;

Wang, Zengjun .

ONCOLOGY LETTERS, 2018, 15 (06) :9051-9060

[43]

Huang CF, 2018, FOOD FUNCT, V9, P6197, DOI [10.1039/c8fo01643g, 10.1039/C8FO01643G]

[44] Crystal structures of catrocollastatin/VAP2B reveal a dynamic, modular architecture of ADAM/adamalysin/reprolysin family proteins [J].

Igarashi, Tomoko ;

Araki, Satohiko ;

Mori, Hidezo ;

Takeda, Soichi .

FEBS LETTERS, 2007, 581 (13) :2416-2422

[45] A metalloprotease-disintegrin, MDC9/meltrin-γ/ADAM9 and PKCδ are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor [J].

Izumi, Y ;

Hirata, M ;

Hasuwa, H ;

Iwamoto, R ;

Umata, T ;

Miyado, K ;

Tamai, Y ;

Kurisaki, T ;

Sehara-Fujisawa, A ;

Ohno, S ;

Mekada, E .

EMBO JOURNAL, 1998, 17 (24) :7260-7272

[46] Adam meets Eph:: An ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans [J].

Janes, PW ;

Saha, N ;

Barton, WA ;

Kolev, MV ;

Wimmer-Kleikamp, SH ;

Nievergall, E ;

Blobel, CP ;

Himanen, JP ;

Lackmann, M ;

Nikolov, DB .

CELL, 2005, 123 (02) :291-304

[47] MicroRNA-543 inhibits proliferation, invasion and induces apoptosis of glioblastoma cells by directly targeting ADAM9 [J].

Ji, Tao ;

Zhang, Xiejun ;

Li, Weiping .

MOLECULAR MEDICINE REPORTS, 2017, 16 (05) :6419-6427

[48] Inhibition of ADAM9 Expression Induces Epithelial Phenotypic Alterations and Sensitizes Human Prostate Cancer Cells to Radiation and Chemotherapy [J].

Josson, Sajni ;

Anderson, Cynthia S. ;

Sung, Shian-Ying ;

Johnstone, Peter A. S. ;

Kubo, Hiroyuki ;

Hsieh, Chia-Ling ;

Arnold, Rebecca ;

Gururajan, Murali ;

Yates, Clayton ;

Chung, Leland W. K. .

PROSTATE, 2011, 71 (03) :232-240

[49] The Effect of Disintegrin-Metalloproteinase ADAM9 in Gastric Cancer Progression [J].

Kim, Jeong Min ;

Jeung, Hei-Cheul ;

Rha, Sun Young ;

Yu, Eun Jeong ;

Kim, Tae Soo ;

Shin, You Keun ;

Zhang, Xianglan ;

Park, Kyu Hyun ;

Park, Seung Woo ;

Chung, Hyun Cheol ;

Powis, Garth .

MOLECULAR CANCER THERAPEUTICS, 2014, 13 (12) :3074-3085

[50] Preferred SH3 Domain Partners of ADAM Metalloproteases Include Shared and ADAM-Specific SH3 Interactions [J].

Kleino, Iivari ;

Jarviluoma, Annika ;

Hepojoki, Jussi ;

Huovila, Ari Pekka ;

Saksela, Kalle .

PLOS ONE, 2015, 10 (03)

← 1 2 3 4 5 6 7 8 9 10 →